Cargando…
VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy
V-domain Ig suppressor of T cell activation (VISTA) is a B7 family member that maintains T cell and myeloid quiescence and is a promising target for combination cancer immunotherapy. During inflammatory challenges, VISTA activity reprograms macrophages towards reduced production of proinflammatory c...
Autores principales: | Yuan, Long, Tatineni, Jahnavi, Mahoney, Kathleen M., Freeman, Gordon J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088836/ https://www.ncbi.nlm.nih.gov/pubmed/33495077 http://dx.doi.org/10.1016/j.it.2020.12.008 |
Ejemplares similares
-
VISTA: A Promising Target for Cancer Immunotherapy?
por: Tagliamento, Marco, et al.
Publicado: (2021) -
VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy
por: Shekari, Najibeh, et al.
Publicado: (2023) -
New emerging targets in cancer immunotherapy: the role of VISTA
por: Tagliamento, Marco, et al.
Publicado: (2020) -
IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy
por: Tang, Xi-Yang, et al.
Publicado: (2022) -
Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy
por: Hong, Shanjuan, et al.
Publicado: (2019)